The bottom line

I’ll conclude this little article review with an anecdote. I recently had dinner with a friend who was telling me about the relative difficulties of raising capital for funding something like an HIV drug trial versus a “small tech startup”. The bottom line was: why spend $200 million on a potentially lifesaving drug when you could fund a couple of hundred startups in hopes of 1 or 2 becoming billion dollar companies? This anecdote left me uncomfortably unable to find a silver lining: how do we as a society make sure that all capital doesn’t end up funding text boxes and photo-sharing instead of other critical innovation?

De aici

Lasa un comentariu